Nichtberger Steven 4

What Happened Steven Nichtberger, President & CEO and a director of Cabaletta Bio (CABA), was granted a derivative award for 674,000 shares on March 2, 2026. The reported acquisition price is $0.00 (no immediate cash outlay), and the award is reported as a derivative/security-based grant (transaction code A). This is a compensation/award grant rather than an open-market purchase or sale.

Key Details

• Transaction date and filing: 2026-03-02 (Form 4 filed same day).
• Transaction type/code: Grant / award (Derivative) — Code A.
• Shares reported: 674,000 shares acquired at $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote (vesting): 25% vests March 1, 2027; the remaining 75% vests in twelve substantially equal quarterly installments thereafter, subject to continued service.
• Timeliness: Filing appears timely (no late-report indication).

Context This grant is a derivative compensation award (likely stock units/options subject to vesting), meaning the shares are not immediately freely tradable and vest over time as a retention/compensation mechanism. Such awards are common for executives and do not by themselves indicate a near-term buy or sell decision.